Literature DB >> 10717161

Hypoxic Stress Proteins: Survival of the Fittest.

.   

Abstract

The importance of tumor microenvironmental in malignant progression has been largely ignored. Tumor cells protect themselves from changes in the microenvironment due to a decrease in nutrients and oxygen by reducing macromolecular synthesis and inducing genes that will promote angiogenesis and tissue remodeling. This ability of transformed cells to survive fluctuations in oxygen tensions is clinically important, as tumors with high hypoxic fractions respond poorly to many forms of cancer therapy. While it is commonly accepted that the decrease in molecular oxygen in hypoxic cells makes them more refractory to killing by agents such as ionizing radiation which use oxygen radical formation, the cessation of division and loss of apoptotic (cell suicide) potential in hypoxic cells are also important in their resistance to killing by radiotherapy and chemotherapy. In this chapter, we will discuss hypoxia-induced stress proteins in regards to three clinically relevant end points: inhibition of cell proliferation, induced of apoptosis, and regulation of genes modulating angiogenesis. Although these three end points may seem unrelated, in fact, they are intimately linked with each other in the cellular response to hypoxia and malignant progression. One of the goals of this review is to inform both clinician and scientist of these interrelationships and discuss how hypoxia selects for tumors that are clonal expansions of cells that have lost their apoptotic ability and have switched to a proangiogenic phenotype.

Entities:  

Year:  1996        PMID: 10717161     DOI: 10.1053/SRAO0060046

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  29 in total

1.  Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.

Authors:  Javier Valencia Julve; Vicente Alonso Orduña; Ricardo Escó Barón; Miriam López-Mata; Agustina Méndez Villamón
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

Review 2.  Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.

Authors:  Matthew M Cooney; Jose Ortiz; Ronald M Bukowski; Scot C Remick
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

3.  Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis.

Authors:  C Koumenis; A Giaccia
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

Review 4.  Effects of irradiation on tumor cell survival, invasion and angiogenesis.

Authors:  Odysseas Kargiotis; Aliki Geka; Jasti S Rao; Athanasios P Kyritsis
Journal:  J Neurooncol       Date:  2010-05-07       Impact factor: 4.130

Review 5.  Treatment resistance of solid tumors: role of hypoxia and anemia.

Authors:  P Vaupel; O Thews; M Hoeckel
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

Review 6.  Imaging hypoxia in gliomas.

Authors:  I Mendichovszky; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 7.  Novel imaging provides new insights into mechanisms of oxygen transport in tumors.

Authors:  Matthew E Hardee; Mark W Dewhirst; Nikita Agarwal; Brian S Sorg
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

8.  Hypoxia blocks in vivo initiation of simian virus 40 replication at a stage preceding origin unwinding.

Authors:  H J Riedinger; M van Betteraey; H Probst
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

Review 9.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

10.  Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration.

Authors:  Zhang Lei; Bo Li; Zhuoshun Yang; Haoshu Fang; Gui-Mei Zhang; Zuo-Hua Feng; Bo Huang
Journal:  PLoS One       Date:  2009-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.